Mark Fisher

Exomedica Ltd. develops and funds medical technology innovation. The firm focus on technology deriving from academic and clinical research. It current portfolio includes innovations in laparoscopy, fertility, gynecology, cancer diagnostics and diabetes. The company was founded on 16 February, 2004 and is headquartered in London, the United Kingdom.

Oncomorph Analysis Ltd is a UK-based software company founded in 2007. The company's mission is to develop innovative technology to automate the analysis of medical images. They are creating software that is designed to model tissues in 3 dimensions and to classify tissue types using information on texture and the histology of disease. By automatically extracting and refining the information yielded by a medical image at point-of-care, Oncomorph Analysis hopes to benefit patients in a number of ways includes eliminating inter-observer variability in the interpretation of medical imaging data, informing the frequency and accuracy of tissue biopsy, automating the normally challenging diagnosis of early stage (non-palpable) disease and combining the diagnostic and surgical planning function of imaging technologies. Applications for the Oncomorph Analysis technology are broad however their aims are focused on the need to standardize the interpretation of medical images at a high throughput. They are currently developing its technology for Magnetic Resonance Imaging (MRI) data, to assist in cancer diagnosis and staging.

Attomarker Ltd. develops medical diagnostic kits. The firm products include array reader technology, allergy, and appex recovery app. Its services include antibody screening, chemical intermediates, and customs synthesis. The company was founded by Andrew Mark Shaw on April 1, 2008 and is headquartered in Exeter, the United Kingdom.